Q2QL83 AF NFT

Cystic fibrosis transmembrane conductance regulator

MOLNFT AF v1 smart contract in GenesisL1 blockchain: 
0xBf7491af3407816DFa88a5EA4c82e8A2B1D721eD
IPFS of NFT metadata: 
bafybeica546nhjpxamshvkijnpgo6nh3osfw73ut2lzr6sinktg7jyggby/metadata.json
IPFS of structure file: 
bafybeiadrklnwbrllcwsmdheam4f7jlvntwxtafysz763sdwbhkbq77q5i/AF-Q2QL83-F1-model_v2.pdb
First NFT owner address (eip-55): 
0x9F605311B7e26e76340423EfAfbE5e2EFc7A0b7C
First NFT owner address (bech32): 
genesis1nas9xydhufh8vdqyy0h6l0j79m785zmurgry0u
Current NFT ID #58978 owner (web3):

First owner GALLERY | EVM EXPLORER | COSMOS EXPLORER

MOLNFT AF v1

NFT id:
58978
Accession (UniProt):
Q2QL83
Name::
Cystic fibrosis transmembrane conductance regulator
Experimental Method:
Predicted structure
Sequence source:
MICROCEBUS MURINUS

NFT data

MolNFT AF v1 is an AlphaFold database of AI predicted Swiss-Prot protein sequences preserved as regular ERC-721 NFT tokens on GenesisL1 blockchain for public free use, research and entertainment:

https://alphafold.ebi.ac.uk/
Jumper, J., Evans, R., Pritzel, A. et al. Highly accurate protein structure prediction with AlphaFold. 
Nature 596, 583–589 (2021). https://doi.org/10.1038/s41586-021-03819-2

MOLNFT Q2QL83 research and analysis (ICN3D with VR)

FASTA sequences

>sp|Q2QL83|CFTR_MICMU Cystic fibrosis transmembrane conductance regulator OS=Microcebus murinus OX=30608 GN=CFTR PE=3 SV=1 MQRSPLEKASVLSKLFFSWTRPILRKGYRQRLELSDIYQIPSADSADNLSEKLEREWDRELASKKNPKLINALRRCFFWRFMFYGILLYLGEVTKAVQPLLLGRIIASYDPDNKVERSIAIYLGIGLCLLFIVRMLLLHPAIFGLHHIGMQMRIAMFSLIYKKILKLSSRVLDKISIGQLVSLLSNNLNKFDEGLALAHFVWIAPLQVMLLMGLLWELLQASAFCGLGFLIVLALFQSGLGRMMMKYRDQRAGKINERLVITSEMIENIQSVKAYCWEEAMEKMIENLRQTELKLTRKAAYVRYFNSSAFFFSGFFVVFLSVLPYALIKGIILRKIFTTISFCIVLRMAVTRQFPWAVQTWYDSLGAINKIQDFLQKQEYKTLEYNLTTTEVVMENVTAFWEEGFGELFEKAKQNSDNRKISNGDNSLFFSNLALLGTPVLKDISFKIERGQLLAVAGSTGAGKTSLLMMIMGELEPSEGKIKHSGRISFCSQFSWIMPGTIKENIIFGVSYDEYRYRSVIKACQLEEDIAKFAEKDNIVLGEGGITLSGGQRARISLARAVYKDADLYLLDSPFGYLDVLTEKEIFESCVCKLMANKTRILVTSKMEHLKKADKILILHEGSSYFYGTFSELQNLRPDFSSKLMGYDSFDQFSAERRNSILTETLRRFSLEGDAAVSWNETKKQSFKQTGEIGEKRKNSILNSINSLRKFSVVQKTPLQMSGIEEDPDEPSERRLSLVPDSEQGEAILPRSNVINTGPTFQGRRRQSVLNLMTHSVNQGQNIHRINAASTRKMSIAPPANLTEMDIYSRRLSQESSLEISEEINEEDLKECFFDDAENIPAVTTWNTYLRYITVHKSLIFVLIWCLVIFLAEVAVSLVLLWLLGNAPAYNKGNSTISANSSYAVIITSTSAYYVFYIYVGVADTLLALGFFRGLPLVHTLITVSKILHHKMLHSVLQAPMSTLNALKAGGILNRFSKDIAILDDLLPLTIFDFIQLLLIVIGAVAVVSVLQPYIFLATVPVIVTFIILRAYFLHTSQQLKQLESEGRSPIFTHLVTSLKGLWTLRAFGRQPYFETLFHKALNLHTANWFLYLSTLRWFQMRIEMVFVIFFIVVTFISILTTGEGEGQVGIILTLAMNIMGTLQWAVNSSIDVDSLMRSVSRVFKFIDMPTEEGKSTRSIKPSKDCHLSKVMVFENPHVKKDDIWPSGGQMTVKDLTARYLDGGNAILENISFSISPGQRVGLLGRTGSGKSTLLSAFLRLLNTEGEIQIDGVSWDSITLQQWRKAFGVIPQKVFIFSGTFRKNLDPYEQWSDQEIWKVADEVGLRSVIEQFPGKLDFVLVDGGYVLSHGHKQLMCLARSVLSKAKILLLDEPSAHLDPITYQIIRRTLKQAFADCTVILCEHRIEAMLECQRFLVIEENNVRQYDSIQKLLSEKSLFRQAISPSDRMKLFPRRNSSKHKSRPPITALKEETEEEVQDTRL